BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 17921969)

  • 1. The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer.
    Witjes JA; Douglass J
    Nat Clin Pract Urol; 2007 Oct; 4(10):542-9. PubMed ID: 17921969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer.
    Grossman HB; Gomella L; Fradet Y; Morales A; Presti J; Ritenour C; Nseyo U; Droller MJ;
    J Urol; 2007 Jul; 178(1):62-7. PubMed ID: 17499283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study.
    Fradet Y; Grossman HB; Gomella L; Lerner S; Cookson M; Albala D; Droller MJ;
    J Urol; 2007 Jul; 178(1):68-73; discussion 73. PubMed ID: 17499291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden.
    Malmström PU; Hedelin H; Thomas YK; Thompson GJ; Durrant H; Furniss J
    Scand J Urol Nephrol; 2009; 43(3):192-8. PubMed ID: 19330681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
    Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
    BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
    Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
    Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hexyl aminolevulinate fluorescence cystoscopy in bladder cancer.
    Sievert KD; Kruck S
    Expert Rev Anticancer Ther; 2009 Aug; 9(8):1055-63. PubMed ID: 19671025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study.
    Jocham D; Witjes F; Wagner S; Zeylemaker B; van Moorselaar J; Grimm MO; Muschter R; Popken G; König F; Knüchel R; Kurth KH
    J Urol; 2005 Sep; 174(3):862-6; discussion 866. PubMed ID: 16093971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hexyl aminolevulinate: 5-ALA hexylester, 5-ALA hexylesther, aminolevulinic acid hexyl ester, hexaminolevulinate, hexyl 5-aminolevulinate, P 1206.
    Drugs R D; 2005; 6(4):235-8. PubMed ID: 15991884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy.
    Schmidbauer J; Witjes F; Schmeller N; Donat R; Susani M; Marberger M;
    J Urol; 2004 Jan; 171(1):135-8. PubMed ID: 14665861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder cancer: results of a prospective Phase II study.
    Witjes JA; Moonen PM; van der Heijden AG
    Eur Urol; 2005 Mar; 47(3):319-22. PubMed ID: 15716194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors.
    Burger M; Stief CG; Zaak D; Stenzl A; Wieland WF; Jocham D; Otto W; Denzinger S
    Urology; 2009 Dec; 74(6):1282-6. PubMed ID: 19819538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blue light cystoscopy for detection and treatment of non-muscle invasive bladder cancer.
    Mark JR; Gelpi-Hammerschmidt F; Trabulsi EJ; Gomella LG
    Can J Urol; 2012 Apr; 19(2):6227-31. PubMed ID: 22512972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance?
    Loidl W; Schmidbauer J; Susani M; Marberger M
    Eur Urol; 2005 Mar; 47(3):323-6. PubMed ID: 15716195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy.
    Zaak D; Karl A; Knüchel R; Stepp H; Hartmann A; Reich O; Bachmann A; Siebels M; Popken G; Stief C
    BJU Int; 2005 Aug; 96(2):217-22. PubMed ID: 16001963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The impact of ALA (5-aminolevulinic acid)-fluorescence detection on the prognosis of superficial bladder cancer].
    Daniltchenko D; Riedl C; Koenig F; Daha LK; Sachs M; Schnorr D
    Aktuelle Urol; 2004 Nov; 35(6):497-501. PubMed ID: 15526230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations.
    Witjes JA; Redorta JP; Jacqmin D; Sofras F; Malmström PU; Riedl C; Jocham D; Conti G; Montorsi F; Arentsen HC; Zaak D; Mostafid AH; Babjuk M
    Eur Urol; 2010 Apr; 57(4):607-14. PubMed ID: 20116164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.
    Burger M; Grossman HB; Droller M; Schmidbauer J; Hermann G; Drăgoescu O; Ray E; Fradet Y; Karl A; Burgués JP; Witjes JA; Stenzl A; Jichlinski P; Jocham D
    Eur Urol; 2013 Nov; 64(5):846-54. PubMed ID: 23602406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation.
    Garfield SS; Gavaghan MB; Armstrong SO; Jones JS
    Can J Urol; 2013 Apr; 20(2):6682-9. PubMed ID: 23587507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors.
    Filbeck T; Pichlmeier U; Knuechel R; Wieland WF; Roessler W
    J Urol; 2002 Jul; 168(1):67-71. PubMed ID: 12050494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.